New ALK CEO: We have to take control
ALK’s new CEO offers no quick fixes, but says the drug group will take control of its destiny and its own products. He is certain that will allow the Danish company to release the potential that is tucked away in the organization.
BY LOUISE WENDT JENSEN
Carsten Hellmann has spent just a week at the helm of allergy drug developer ALK, but he is not pushing pencils and worrying about what to do first. His focus is clear and one task takes top priority from the get go: the company’s situation on the US market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
.JPG)
“When it happens you get the wind knocked out of you”
For abonnenter
ALK gets a slap on the wrist from the FDA
For abonnenter
ALK readies new EU application for allergy tablet
For abonnenter
